Table 1 Baseline characteristics of patients with SR-aGVHD in the two groups

Age, median (range), years

32 (18–68)

33 (18–68)

31 (18–62)

0.633

Gender, n (%)

0.292

 Male

68 (52.3%)

37 (56.9%)

31 (47.7%)

 Female

62 (47.7%)

28 (43.1%)

34 (52.3%)

Disease, n (%)

0.275

 AML

49 (37.7%)

26 (40.0%)

23 (35.4%)

 ALL

32 (24.6%)

15 (23.1%)

17 (26.15%)

 MDS

28 (21.5%)

11 (16.9%)

17 (26.15%)

 SAA

13 (10.0%)

6 (9.2%)

7 (10.8%)

 others

8 (6.2%)

7 (10.8%)

1 (1.5%)

Donor type, n (%)

0.366

 Haploidentical related donor

63 (96.92%)

62 (95.38%)

 Identical sibling donor

1 (1.54%)

3 (4.62%)

 Unrelated donor

1 (1.54%)

0 (0.00%)

 ABO blood type, n (%)

0.845

 Matched

40 (61.5%)

39 (60.0%)

 Mismatched

25 (38.5%)

26 (40.0%)

Conditioning regimen, n (%)

0.888

 BU/CY-based

104 (80%)

51 (78.5%)

53 (81.5%)

 BU/FLU-based

20 (15.4%)

11 (16.9%)

9 (13.9%)

 TBI-based

6 (4.6%)

3 (4.6%)

3 (4.6%)

GVHD prophylaxis

0.648

 CsA, MMF, MTX+ low-dose PTCy

6 (4.6%)

2 (3.1%)

3 (4.6%)

 CsA, MMF, MTX

124 (95.4%)

63 (96.9%)

62 (95.4%)

 Transplanted total nucleated cell dose, ×10⁸/kg, median (range)

9.67 (6.07–16.60)

10.17 (5.52–18.93)

0.193

 Transplanted CD34⁺ cell dose (×10⁶/kg, median, range)

3.24 (1.10–8.66)

2.71 (0.71–7.50)

0.065

Stem cell source

0.193

 PBSCs

113 (86.9%)

59 (90.8%)

54 (83.1%)

 PBSCs+BM

17 (13.1%)

6 (9.2%)

11 (16.9%)

Patients achieved WBC engraftment, n (%)

 Patients achieved PLT engraftment before day 90, n (%)

59 (90.77%)

55 (84.62%)

0.297

 WBC engraftment time (post-HSCT days)

12 (8–19)

12 (11–20)

0.137

 PLT engraftment time (post-HSCT days)^a

11 (8–75)

13 (9–80)

0.221